Table 3. Characteristics of study groups.
For disease groups, all measurements were taken at the time of trial sample unless otherwise specified. Plus-minus values are means ± SD. ‡ For COVID-19 ARDS group, data provided for nine patients that were receiving invasive mechanical ventilation (n=8) or non-invasive ventilation (n=1) at the time of the sample. The three other patients were receiving high flow nasal oxygen at the time of the sample, so these measurements were not available. ARDS: acute respiratory distress syndrome; APACHE II: acute physiology and chronic health evaluation II; FCI: Functional Comorbidity Index; ICU: intensive care unit; PaO2: arterial partial pressure of oxygen; SpO 2: peripheral oxygen saturation; PEEP: positive end-expiratory pressure.
| Characteristic | Non-COVID-19 ARDS
(n = 7) |
COVID-19 ARDS
(n = 12) |
Moderate COVID-19
(n = 3) |
|---|---|---|---|
| Demographics | |||
| Age – yr | 48.7±9.3 | 59.0±14.5 | 85.7±5.7 |
| Female sex – no. (%) | 5 (71.4) | 3 (25.0) | 2 (66.7) |
| Body-mass index – kg/m 2 | 27.7±2.9 | 33.1±8.5 | 19.9±3.3 |
| Clinical data | |||
| Cause of ARDS | |||
| Pulmonary – no. (%) | 5 (71.4) | 12 (100.0) | |
| Extra-pulmonary | 2 (28.6) | 0 (0.0) | |
| APACHE II Score | 18.1±5.4 | 14.8±3.9 | |
| Functional Comorbidity Index | 1.4±0.8 | 1±0.7 | |
| Lowest SpO
2 in 6 hrs prior to ICU
admission |
89.4±6.0 | 77±21 | |
| Organ injury and support | |||
| Invasive mechanical ventilation – no. (%) | 7 (100.0) | 8 (66.7) | |
| Renal replacement therapy – no. (%) | 1 | 0 | |
| Vasopressors – no. (%) | 7 (100.0) | 4 (33.3) | |
| ARDS Therapy ‡ | |||
| Peak pressure (cmH 2O) | 25.0±7.2 | 24±6 | |
| PEEP (cmH 2O) | 7.9±3.2 | 10±4 | |
| Tidal volume (ml) | 366.0±59.5 | 402±63 | |
| Respiratory rate (breaths/min) | 28.12±2.3 | 23.1±3.8 | |
| Medications | |||
| Lopinavir-Ritonavir – no. (%) | 0 (0.0) | 3 (25.0) | 0 (0.0) |
| Hydroxychloroquine – no. (%) | 0 (0.0) | 2 (16.7) | 0 (0.0) |
| Dexamethasone – no. (%) | 0 (0.0) | 9 (75.0) | 0 (0.0) |